-
New antibody combination can significantly improve the therapeutic effect of cancer immunotherapy
Time of Update: 2020-01-07
An international research team recently published a paper in the Journal of the National Academy of Sciences, saying that animal experiments show that a combination of "three in one" antibodies can si
-
First line immunotherapy for bladder cancer! Merck / Pfizer bavencio combined with best support nursing phase III clinical significantly improved overall survival (OS)!
Time of Update: 2020-01-07
January 7, 2020 / Biovalley BIOON / -- Pfizer, a US pharmaceutical giant, and Merck KGaA, a partner, recently jointly announced that the evaluation of bavencio (avelumab), a PD-L1 tumor immunotherapy,
-
New drug for multiple myeloma! Tj202 / mor202, the first case of clinical trial in mainland China, was administered!
Time of Update: 2020-01-06
January 6, 2020 / Biovalley BIOON / - Tianjing Biotechnology (Shanghai) Co., Ltd (hereinafter referred to as "Tianjing biology") recently announced that tj202 / mor202, the innovative human CD38 antib
-
The synergistic effect of the combination of anti-angiogenesis drugs and cancer immunotherapy has been proven again!
Time of Update: 2020-01-06
Recently, a study conducted by scientists from the University of Basel and Roche in animal models has proved the synergistic effect of anti angioproliferative drugs combined with cancer immunotherapy
-
Develop innovative treatments for gastric cancer, BeiGene reached cooperation
Time of Update: 2020-01-05
On January 3, leap therapeutics and beigene jointly announced that they had reached an exclusive option and license agreement on the clinical development and promotion of DKK1 targeted antagonist dkn-
-
The study found that the influence factors of tumor immune efficacy difference
Time of Update: 2020-01-04
Immunosuppressive therapy is one of the most potential therapies to cure tumor However, the therapeutic effect of this method varies greatly in different people, different tumors and different individ
-
Heavy marriage! Baiji Shenzhou announced the global tumor strategic cooperation and equity investment with Amgen, and Amgen invested 20 billion yuan!
Time of Update: 2020-01-04
January 4, 2020 / BIOON / -- beigene is a biomedical company in the commercial stage, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for can
-
The first new drug in 20 years! AstraZeneca immunotoxin lumoxiti applied for listing in the European Union to treat hair cell leukemia (HCl)
Time of Update: 2020-01-04
January 4, 2020 / BIOON / -- the French pharmaceutical company, innate Pharma SA, recently announced that the European Drug Administration (EMA) has accepted lumoxiti (moxetummab Pasudotox's marketing
-
Car-t cell therapy killer! Tafasitamab, a new type of immunoenhancement monoclonal antibody targeting at CD19, has been applied for marketing in the United States to treat B-cell tumors!
Time of Update: 2019-12-31
December 31, 2019 / BIOON / -- morphasys is a clinical stage German biopharmaceutical company dedicated to developing innovative and differentiated therapies for critical patients It is worth mentioni
-
Targeted treatment of ovarian cancer! US FDA defines the accelerated approval path of mirvetuximab, a new ADC drug, for the treatment of patients with folate receptor positive platinum resistance
Time of Update: 2019-12-30
December 30, 2019 / BIOON / -- immunogen is a clinical stage biotechnology company focusing on the development of a new generation of antibody drug conjugate (ADC) to improve the prognosis of cancer p
-
Target CCR5 for breast cancer! Leonlimab has strong therapeutic potential in triple negative breast cancer (TNBC) and metastatic breast cancer (MBC)!
Time of Update: 2019-12-30
December 30, 2019 news / BIOON / -- cytodyn is a late clinical biotechnology company focusing on the development of a new humanized CCR5 antagonist, leonlimab (pro140), for a variety of treatment indi
-
New target immunotoxin! Vicinium initiated rolling submission for the treatment of high-risk BCG unresponsive non muscle invasive bladder cancer (NMIBC)!
Time of Update: 2019-12-29
December 29, 2019 / Biogen / -- sesen bio is a biopharmaceutical company in the late clinical stage, focusing on the development of targeted fusion protein therapy for cancer Recently, the company ann
-
Immune checkpoint + microbiome! Bristol Myers Squibb and Vedanta launched the first human study to evaluate the treatment of multiple cancers with opdivo / ve800
Time of Update: 2019-12-29
December 29, 2019 news / BIOON / -- Vedanta Biosciences is a clinical stage microbiome company, focusing on the development of a new type of therapy based on a reasonably designed human bacterial comb
-
Car-t cell therapy killer! CD19 targeting a new type of FC optimized immunoenhancer monoclonal antibody tafasitamab has a strong therapeutic effect on B cell tumor!
Time of Update: 2019-12-28
December 28, 2019 / BIOON / -- morphasys is a clinical German biopharmaceutical company dedicated to developing innovative and differentiated therapies for critical patients It is worth mentioning tha
-
Domestic anti PD-1 therapy! Baiji baize'an (tirelizumab injection) has been approved by the National Drug Administration (nmpa) for listing!
Time of Update: 2019-12-28
December 27, 2019 / BIOON / -- beigene is a biomedical company in the commercial stage, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for c
-
New darpin immunotherapy! Molecular partners mp0250 is qualified as FDA orphan drug to treat multiple myeloma!
Time of Update: 2019-12-28
December 27, 2019 / BIOON / -- molecular partners is a clinical stage biotechnology company, taking the lead in using darpin ® therapy to treat serious diseases Recently, the company announced that th
-
The first three negative breast cancer ADC drug! Immunomedics potential blockbuster sacituzumab govitecan is under review in the US!
Time of Update: 2019-12-27
December 27, 2019 / BIOON / -- immunomedics is a clinical stage biopharmaceutical company, focusing on the development of monoclonal antibody based therapies for targeted treatment of cancer and other
-
First line immunotherapy for lung cancer! BMS combination therapy opdivo + yevoy applied for new indications in Japan to treat patients with PD-L1 positive NSCLC!
Time of Update: 2019-12-27
December 27, 2019 / BIOON / -- Ono Pharmaceutical and bmskk recently announced that they have submitted a supplementary application in Japan to change the production and marketing approval of two drug
-
The first new drug of Globo h target! Taiwan Haoding antibody drug coupling compound obi-999 was awarded orphan drug qualification by US FDA to treat pancreatic cancer!
Time of Update: 2019-12-27
December 27, 2019 / BIOON / -- Taiwan Haoding Biotechnology Co., Ltd (Obi Pharma, Inc., hereinafter referred to as Haoding) recently announced that the U.S Food and Drug Administration (FDA) has grant
-
The first combination therapy without chemotherapy for follicular lymphoma! Bristol Myers Squibb Revlimid + rituximab has been approved by the European Union!
Time of Update: 2019-12-23
December 23, 2019 / bioin / - Bristol Myers Squibb (BMS) recently announced that the European Commission (EC) has approved a new indication of Revlimid (lenalidomide, lenalidomide) - combination of ri
